Postmenopausal estrogens can reduce menopausal symptoms, risk of osteoporotic
fractures, and probably coronary heart disease. Adverse effects include venous
thrombosis and cancers of the endometrium and breast. The increased risk of
breast cancer is primarily among current or very recent estrogen users and
is directly related to duration of use.1
Addition of progestin to estrogen largely mitigates the increased risk
of endometrial cancer,2 and combination therapy
(opposed estrogen) has become the standard hormonal regimen for women with
a uterus. The impact of combined estrogen and progestin on risk of breast
cancer has been controversial. Although protective effects analogous to those
for endometrial cancer have been hypothesized for breast cancer, cyclical
use of progestin to simulate normal menstrual cycles increases mitotic activity
in the breast.3
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 34
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.